Tratamiento del edema de macula diabético clinicamente significativo con Ranibizumab (LUCENTIS) intravitreo. TREATMENT OF DIABETIC CLINICALLY SIGNIFICANT MACULAR EDEMA WITH INTRAVITREOUS RANIBIZUMAB (LUCENTIS)

HOSPITAL SAN PEDRO0 个研究点开始时间: 2009年2月4日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Diabetic type 1 and 2 patients.
•Diabetic macular edema, diffuse, refractory to laser treatment (decrease in visual acuity during the last six months treatment, with central thickness >250 microns.
•Less than very severe diabetic retinopathy.
•Visual acuity >20/320 Snellen (24 letters ETDRS).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Tractional macular edema diagnosed in optical coherence tomography.
•Cataract that can require surgery in the following one year.
•Uncontrolled hypertension with medical treatment (>150/95 mm Hg)
•Bad glycemic control (HbA1C > 10%).
•Severe nephropathy.
•Previous hearth attack.
•Previous brain vascular disease.
•Pregnancy or intention of it during the following one year (pregnancy test required)
•Active ocular inflammation
•Previous vitrectomy in the study eye.
•Previous anti-glaucoma treatment that can increase macular edema.
•Use of any drug that can be toxic to the macula.
•Previous use of anti-angiogenic drug or intravitreous steroid in the study eye.

发起方

HOSPITAL SAN PEDRO